TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of “Moderate Buy” by Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $127.1818.

A number of equities research analysts have commented on the company. Morgan Stanley raised their price target on TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Evercore ISI assumed coverage on TransMedics Group in a report on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price target on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $142.00 price target on shares of TransMedics Group in a report on Tuesday, October 14th. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Monday, August 25th.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $117.63 on Monday. TransMedics Group has a one year low of $55.00 and a one year high of $145.50. The stock’s fifty day moving average is $116.52 and its 200 day moving average is $113.94. The stock has a market cap of $4.01 billion, a P/E ratio of 60.95 and a beta of 2.08. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to analysts’ expectations of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period last year, the firm earned $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that TransMedics Group will post 1 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Amalgamated Bank raised its stake in shares of TransMedics Group by 0.8% during the second quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after acquiring an additional 80 shares in the last quarter. Canada Pension Plan Investment Board raised its stake in shares of TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after acquiring an additional 100 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of TransMedics Group by 24.5% during the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock valued at $72,000 after acquiring an additional 108 shares in the last quarter. CWM LLC increased its holdings in TransMedics Group by 18.5% during the third quarter. CWM LLC now owns 897 shares of the company’s stock valued at $101,000 after buying an additional 140 shares during the period. Finally, Ameritas Investment Partners Inc. increased its holdings in TransMedics Group by 4.4% during the second quarter. Ameritas Investment Partners Inc. now owns 3,394 shares of the company’s stock valued at $455,000 after buying an additional 142 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.